California Public Employees Retirement System Purchases 15,588 Shares of Alexion Pharmaceuticals, Inc. (ALXN)

California Public Employees Retirement System raised its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 3.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 463,579 shares of the biopharmaceutical company’s stock after acquiring an additional 15,588 shares during the period. California Public Employees Retirement System owned approximately 0.21% of Alexion Pharmaceuticals worth $65,035,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Jennison Associates LLC increased its position in shares of Alexion Pharmaceuticals by 720.0% during the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after purchasing an additional 4,682,336 shares during the last quarter. BlackRock Inc. increased its position in shares of Alexion Pharmaceuticals by 7.0% during the 2nd quarter. BlackRock Inc. now owns 19,926,265 shares of the biopharmaceutical company’s stock valued at $2,424,428,000 after purchasing an additional 1,298,185 shares during the last quarter. Third Point LLC bought a new position in shares of Alexion Pharmaceuticals during the 2nd quarter valued at approximately $152,088,000. Janus Henderson Group PLC increased its position in shares of Alexion Pharmaceuticals by 1,697.6% during the 2nd quarter. Janus Henderson Group PLC now owns 1,145,918 shares of the biopharmaceutical company’s stock valued at $139,424,000 after purchasing an additional 1,082,171 shares during the last quarter. Finally, TIAA CREF Investment Management LLC increased its position in shares of Alexion Pharmaceuticals by 42.2% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 3,219,961 shares of the biopharmaceutical company’s stock valued at $391,773,000 after purchasing an additional 955,578 shares during the last quarter. 94.33% of the stock is currently owned by institutional investors and hedge funds.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at $113.54 on Thursday. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96. The stock has a market capitalization of $25,370.00, a price-to-earnings ratio of 22.88, a PEG ratio of 1.22 and a beta of 1.18.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The business had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. During the same quarter in the prior year, the company earned $1.23 EPS. The business’s revenue was up 7.5% compared to the same quarter last year. research analysts forecast that Alexion Pharmaceuticals, Inc. will post 4.82 earnings per share for the current fiscal year.

ALXN has been the topic of several research analyst reports. Royal Bank of Canada upped their price objective on Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. SunTrust Banks reaffirmed a “buy” rating and issued a $180.00 price objective (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Deutsche Bank reaffirmed a “buy” rating and issued a $158.00 price objective (up previously from $153.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Leerink Swann reaffirmed a “buy” rating and issued a $182.00 price objective on shares of Alexion Pharmaceuticals in a research report on Monday, September 25th. Finally, Stifel Nicolaus cut their price objective on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a research report on Tuesday, October 24th. Four equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $155.47.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://sportsperspectives.com/2017/12/14/california-public-employees-retirement-system-purchases-15588-shares-of-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply